Scott Schoenhaus
Stock Analyst at Keybanc
(1.13)
# 3,509
Out of 4,735 analysts
90
Total ratings
26.92%
Success rate
-10.12%
Average return
Main Sectors:
Stocks Rated by Scott Schoenhaus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Overweight | $285 → $255 | $223.04 | +14.33% | 15 | Jan 8, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $40 → $35 | $31.66 | +10.55% | 2 | Jan 8, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $12 → $10 | $6.88 | +45.35% | 6 | Jan 8, 2025 | |
| PHR Phreesia | Maintains: Overweight | $28 → $30 | $27.35 | +9.69% | 6 | Jan 8, 2025 | |
| ODD Oddity Tech | Maintains: Overweight | $50 → $52 | $45.06 | +15.40% | 2 | Jan 8, 2025 | |
| LFMD LifeMD | Maintains: Overweight | $10 → $7 | $5.17 | +35.40% | 3 | Jan 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $6 | $4.71 | +27.39% | 5 | Jan 8, 2025 | |
| DOCS Doximity | Maintains: Overweight | $70 → $65 | $55.52 | +17.07% | 2 | Jan 8, 2025 | |
| ABSI Absci | Maintains: Overweight | $6 → $5 | $3.22 | +55.28% | 5 | Jan 8, 2025 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $5 → $4 | $3.06 | +30.72% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 | $5.68 | +58.45% | 5 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $3.14 | +43.31% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $6.98 | +57.59% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $12.61 | +58.60% | 3 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $21.33 | +17.21% | 3 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $100 | $104.74 | -4.53% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $21.48 | - | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $42.91 | - | 8 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Weight | n/a | $9.50 | - | 4 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $180 → $250 | $205.69 | +21.54% | 2 | Apr 16, 2021 |
Veeva Systems
Jan 8, 2025
Maintains: Overweight
Price Target: $285 → $255
Current: $223.04
Upside: +14.33%
Simulations Plus
Jan 8, 2025
Maintains: Overweight
Price Target: $40 → $35
Current: $31.66
Upside: +10.55%
Recursion Pharmaceuticals
Jan 8, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $6.88
Upside: +45.35%
Phreesia
Jan 8, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $27.35
Upside: +9.69%
Oddity Tech
Jan 8, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $45.06
Upside: +15.40%
LifeMD
Jan 8, 2025
Maintains: Overweight
Price Target: $10 → $7
Current: $5.17
Upside: +35.40%
GoodRx Holdings
Jan 8, 2025
Maintains: Overweight
Price Target: $7 → $6
Current: $4.71
Upside: +27.39%
Doximity
Jan 8, 2025
Maintains: Overweight
Price Target: $70 → $65
Current: $55.52
Upside: +17.07%
Absci
Jan 8, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $3.22
Upside: +55.28%
AbCellera Biologics
Jan 8, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.06
Upside: +30.72%
Jan 8, 2025
Upgrades: Overweight
Price Target: $9
Current: $5.68
Upside: +58.45%
Dec 9, 2024
Initiates: Overweight
Price Target: $4.5
Current: $3.14
Upside: +43.31%
Nov 13, 2024
Maintains: Overweight
Price Target: $10 → $11
Current: $6.98
Upside: +57.59%
Jul 11, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $12.61
Upside: +58.60%
Jul 11, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $21.33
Upside: +17.21%
Jun 5, 2024
Maintains: Overweight
Price Target: $95 → $100
Current: $104.74
Upside: -4.53%
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $21.48
Upside: -
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $42.91
Upside: -
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $9.50
Upside: -
Apr 16, 2021
Upgrades: Overweight
Price Target: $180 → $250
Current: $205.69
Upside: +21.54%